Use of isogenic human cancer cells for high-throughput screening and drug discovery (Q34093306)

31 July 2017

Use of isogenic human cancer cells for high-throughput screening and drug discovery (English)

1 reference

31 July 2017

0 references

1 reference

3

Vogelstein B

1 reference

31 July 2017

4

Kinzler KW

1 reference

31 July 2017

Torrance CJ

1

1 reference

31 July 2017

Agrawal V

series ordinal

2

1 reference

31 July 2017

language of work or name

1 reference

1 October 2001

1 reference

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

10

1 reference

31 July 2017

940-945

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1001-940

31 July 2017

0 references

cites work

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

2,3,5-Triphenyl tetrazolium chloride (TTC) reduction as exponential growth phase marker for mammalian cells in culture and for myeloma hybridization experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Mechanism-based target identification and drug discovery in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Understanding Ras: 'it ain't over 'til it's over'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Mouse genetics/genomics: an effective approach for drug target discovery and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Transgenic gene knock-outs: functional genomics and therapeutic target selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

Signal-transduction cascades as targets for therapeutic intervention by natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

7 January 2021

The G-C specific DNA binding drug, mithramycin, selectively inhibits transcription of the C-MYC and C-HA-RAS genes in regenerating liver

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

7 January 2021

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

7 January 2021

Green fluorescent protein (GFP): applications in cell-based assays for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNBT1001-940

7 January 2021

Identifiers

DOI

10.1038/NBT1001-940

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference